JP2016521975A - 遺伝的状態の処置のための方法および組成物 - Google Patents
遺伝的状態の処置のための方法および組成物 Download PDFInfo
- Publication number
- JP2016521975A JP2016521975A JP2016514094A JP2016514094A JP2016521975A JP 2016521975 A JP2016521975 A JP 2016521975A JP 2016514094 A JP2016514094 A JP 2016514094A JP 2016514094 A JP2016514094 A JP 2016514094A JP 2016521975 A JP2016521975 A JP 2016521975A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cell
- sequence
- plant
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
Abstract
Description
本出願は、2013年5月15日に出願された米国仮特許出願第61/823,689号の利益を主張し、その開示は本明細書においてその全体が参考として援用される。
本開示は、ゲノム遺伝子操作の分野にある。
このCas9タンパク質は、少なくとも2つのヌクレアーゼドメインを有する:一方のヌクレアーゼドメインは、HNHエンドヌクレアーゼと類似しているが、他方は、Ruvエンドヌクレアーゼドメインと似ている。HNH型ドメインは、crRNAと相補的なDNA鎖を開裂させることを担うようであるが、Ruvドメインは、非相補鎖を開裂させる。
crRNA−tracrRNA複合体の要求は、crRNAおよびtracrRNAのアニーリングによって通常形成されるヘアピンを含む遺伝子操作された「単一ガイドRNA」(sgRNA)の使用によって回避され得る(Jinekら(2012年)Science 337巻:816頁およびCongら(2013年)Sciencexpress/10.1126/science.1231143を参照)。S.pyrogenesでは、遺伝子操作されたtracrRNA:crRNA融合物またはsgRNAは、Cas会合したRNAと標的DNAとの間で二本鎖RNA:DNAヘテロ二量体が形成する場合に、Cas9が標的DNAを開裂するようにガイドする。Cas9タンパク質とPAM配列を含む遺伝子操作されたsgRNAとを含むこの系は、RNAガイドされるゲノム編集に使用されており(Ramalingam同書を参照)、ZFNおよびTALENと類似の編集効率で、in vivoでゼブラフィッシュ胚ゲノム編集に有用である(Hwangら(2013年)Nature Biotechnology 31巻(3号):227頁を参照)。
本明細書に開示される方法、ならびに組成物の調製および使用の実施は、特に示さない限り、本技術分野の技術範囲内の、分子生物学、生化学、クロマチン構造および分析、計算機化学、細胞培養、組換えDNAならびに関連分野における従来の技術を用いる。これらの技術は、文献中に完全に説明されている。例えば、SambrookらMOLECULAR CLONING: A LABORATORY MANUAL、第2版、Cold Spring Harbor Laboratory Press、1989年および第3版、2001年;Ausubelら、CURRENT PROTOCOLS IN MOLECULAR BIOLOGY、John Wiley & Sons、New York、1987年および定期的更新;シリーズMETHODS IN ENZYMOLOGY、Academic Press、San Diego;Wolffe、CHROMATIN STRUCTURE AND FUNCTION、第3版、Academic Press、San Diego、1998年;METHODS IN ENZYMOLOGY、304巻、「Chromatin」(P.M. WassarmanおよびA. P. Wolffe編)、Academic Press、San Diego、1999年;ならびにMETHODS IN MOLECULAR BIOLOGY、119巻、「Chromatin Protocols」(P.B. Becker編)Humana Press、Totowa、1999年を参照されたい。
用語「核酸」、「ポリヌクレオチド」および「オリゴヌクレオチド」は、相互交換可能に使用され、直鎖状または環状コンフォメーションの、一本鎖形態または二本鎖形態のいずれかの、デオキシリボヌクレオチドまたはリボヌクレオチドのポリマーを指す。本開示の目的のため、これらの用語は、ポリマーの長さに関して限定的であると解釈すべきではない。これらの用語は、天然ヌクレオチドの公知のアナログ、ならびに塩基、糖および/またはリン酸部分(例えば、ホスホロチオエート骨格)において修飾されたヌクレオチドを包含し得る。一般に、特定のヌクレオチドのアナログは、同じ塩基対合特異性を有する;即ち、Aのアナログは、Tと塩基対合する。
CRISPR/Cas系
他のCasタンパク質
B.機能的ドメイン
CRISPR/CasのRNA構成成分
ドナー
送達
植物の送達
所与のZFNに指定された遺伝子座のゲノム編集の際に使用するためのガイドRNA(sgRNAまたはgRNA)の配列は、(i)ZFNヘテロ二量体の認識配列を、関連ゲノム(ヒト、マウスまたは特定の植物種)の参照配列とアライメントし、(ii)ZFN−ハーフ部位間のスペーサー領域を同定し、(iii)スペーサー領域に最も近いモチーフG[N20]GGの位置を同定し(1つよりも多いそのようなモチーフがスペーサーと重複する場合、このスペーサーに対して中心にあるモチーフが選択された)、(iv)gRNAのコアとしてそのモチーフを使用することによって同定された。表1は、CRISPR/Cas系を用いて使用するための一連のsgRNAを示す。目的の細胞を、表1のsgRNAと接触させて遺伝子操作する。
実施例1に記載されているように、sgRNAの設計は、種々の考慮、即ち(i)ZFNヘテロ二量体の認識配列を、関連ゲノム(ヒト、マウスまたは特定の植物種)の参照配列とアラインメントし、(ii)ZFN−ハーフ部位間のスペーサー領域を同定し、(iii)使用されているCas9タンパク質に関連し、スペーサー領域に最も近いPAMモチーフ(例えば、S.pyogenesのCas9を使用している場合のG[N17−20](G/A)G)の位置を同定し(1つよりも多いそのようなモチーフがスペーサーと重複する場合、スペーサーに対して中心にあるモチーフが選択された)、(iv)sgRNAのコアとしてそのモチーフを使用することを通して達成される。
Claims (15)
- 細胞において内因性遺伝子の発現を修飾する方法であって、前記方法が、前記内因性遺伝子中の標的部位を認識する単一ガイドRNAを含む第1の核酸分子および機能的ドメインをコードする第2の核酸分子を前記細胞に投与するステップを含み、前記機能的ドメインが、前記標的部位上で前記単一ガイドRNAと会合し、それによって、前記内因性遺伝子の発現を修飾する、方法。
- 前記機能的ドメインが、転写活性化ドメイン、転写抑制ドメインおよびヌクレアーゼドメインからなる群から選択される、請求項1に記載の方法。
- 前記機能的ドメインが、IIS型制限酵素ヌクレアーゼドメインまたはCasタンパク質である、請求項2に記載の方法。
- 前記機能的ドメインが転写活性化ドメインであり、前記内因性遺伝子の発現が増加される、請求項2に記載の方法。
- 前記機能的ドメインが転写抑制ドメインであり、前記内因性遺伝子の発現が阻害される、請求項2に記載の方法。
- 前記機能的ドメインがヌクレアーゼであり、前記内因性遺伝子が開裂される、請求項2に記載の方法。
- 前記ヌクレアーゼドメインが、前記Casタンパク質によって含まれる、請求項6に記載の方法。
- 前記Casタンパク質が、もう1つのヌクレアーゼ開裂ドメインを含む、請求項7に記載の方法。
- 前記細胞が、哺乳動物細胞または植物細胞である、請求項1〜8のいずれかに記載の方法。
- 前記哺乳動物細胞が幹細胞である、請求項9に記載の方法。
- 前記内因性遺伝子が、哺乳動物βグロビン遺伝子(HBB)、ガンマグロビン遺伝子(HBG1)、B細胞リンパ腫/白血病11A(BCL11A)遺伝子、Kruppel様因子1(KLF1)遺伝子、CCR5遺伝子、CXCR4遺伝子、PPP1R12C(AAVS1)遺伝子、ヒポキサンチンホスホリボシルトランスフェラーゼ(HPRT)遺伝子、アルブミン遺伝子、第VIII因子遺伝子、第IX因子遺伝子、ロイシンリッチリピートキナーゼ2(LRRK2)遺伝子、ハンチンチン(Hungtingin)(Htt)遺伝子、ロドプシン(RHO)遺伝子、嚢胞性線維症膜コンダクタンス調節因子(CFTR)遺伝子、サーファクタントタンパク質B遺伝子(SFTPB)、T細胞受容体アルファ(TRAC)遺伝子、T細胞受容体ベータ(TRBC)遺伝子、プログラム細胞死1(PD1)遺伝子、細胞傷害性Tリンパ球抗原4(CTLA−4)遺伝子、ヒト白血球抗原(HLA)A遺伝子、HLA B遺伝子、HLA C遺伝子、HLA−DPA遺伝子、HLA−DQ遺伝子、HLA−DRA遺伝子、LMP7遺伝子、抗原ペプチド輸送体(TAP)1遺伝子、TAP2遺伝子、タパシン遺伝子(TAPBP)、クラスII主要組織適合複合体トランス活性化因子(CIITA)遺伝子、ジストロフィン遺伝子(DMD)、グルココルチコイド受容体遺伝子(GR)、IL2RG遺伝子およびRFX5遺伝子からなる群から選択される、請求項1〜9のいずれかに記載の方法。
- 前記内因性遺伝子が、植物FAD2遺伝子、植物FAD3遺伝子、植物ZP15遺伝子、植物KASII遺伝子、植物MDH遺伝子および植物EPSPS遺伝子からなる群から選択される、請求項1〜9のいずれかに記載の方法。
- 哺乳動物βグロビン遺伝子(HBB)、ガンマグロビン遺伝子(HBG1)、B細胞リンパ腫/白血病11A(BCL11A)遺伝子、Kruppel様因子1(KLF1)遺伝子、CCR5遺伝子、CXCR4遺伝子、PPP1R12C(AAVS1)遺伝子、ヒポキサンチンホスホリボシルトランスフェラーゼ(HPRT)遺伝子、アルブミン遺伝子、第VIII因子遺伝子、第IX因子遺伝子、ロイシンリッチリピートキナーゼ2(LRRK2)遺伝子、ハンチンチン(Htt)遺伝子、ロドプシン(RHO)遺伝子、嚢胞性線維症膜コンダクタンス調節因子(CFTR)遺伝子、サーファクタントタンパク質B遺伝子(SFTPB)、T細胞受容体アルファ(TRAC)遺伝子、T細胞受容体ベータ(TRBC)遺伝子、プログラム細胞死1(PD1)遺伝子、細胞傷害性Tリンパ球抗原4(CTLA−4)遺伝子、ヒト白血球抗原(HLA)A遺伝子、HLA B遺伝子、HLA C遺伝子、HLA−DPA遺伝子、HLA−DQ遺伝子、HLA−DRA遺伝子、LMP7遺伝子、抗原ペプチド輸送体(TAP)1遺伝子、TAP2遺伝子、タパシン遺伝子(TAPBP)、クラスII主要組織適合複合体トランス活性化因子(CIITA)遺伝子、ジストロフィン遺伝子(DMD)、グルココルチコイド受容体遺伝子(GR)、IL2RG遺伝子およびRFX5遺伝子からなる群から選択される内因性遺伝子に結合する、単一ガイドRNA。
- 植物FAD2遺伝子、植物FAD3遺伝子、植物ZP15遺伝子、植物KASII遺伝子、植物MDH遺伝子および植物EPSPS遺伝子からなる群から選択される内因性遺伝子に結合する、単一ガイドRNA。
- 配列番号149〜215からなる群から選択される、請求項13または14に記載の単一ガイドRNA。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019010055A JP6964103B2 (ja) | 2013-05-15 | 2019-01-24 | 遺伝的状態の処置のための方法および組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361823689P | 2013-05-15 | 2013-05-15 | |
US61/823,689 | 2013-05-15 | ||
PCT/US2014/038216 WO2014186585A2 (en) | 2013-05-15 | 2014-05-15 | Methods and compositions for treatment of a genetic condition |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019010055A Division JP6964103B2 (ja) | 2013-05-15 | 2019-01-24 | 遺伝的状態の処置のための方法および組成物 |
JP2020087329A Division JP2020120690A (ja) | 2013-05-15 | 2020-05-19 | 遺伝的状態の処置のための方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016521975A true JP2016521975A (ja) | 2016-07-28 |
JP2016521975A5 JP2016521975A5 (ja) | 2017-03-30 |
Family
ID=51899008
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016514094A Withdrawn JP2016521975A (ja) | 2013-05-15 | 2014-05-15 | 遺伝的状態の処置のための方法および組成物 |
JP2019010055A Active JP6964103B2 (ja) | 2013-05-15 | 2019-01-24 | 遺伝的状態の処置のための方法および組成物 |
JP2020087329A Withdrawn JP2020120690A (ja) | 2013-05-15 | 2020-05-19 | 遺伝的状態の処置のための方法および組成物 |
JP2022090175A Pending JP2022107776A (ja) | 2013-05-15 | 2022-06-02 | 遺伝的状態の処置のための方法および組成物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019010055A Active JP6964103B2 (ja) | 2013-05-15 | 2019-01-24 | 遺伝的状態の処置のための方法および組成物 |
JP2020087329A Withdrawn JP2020120690A (ja) | 2013-05-15 | 2020-05-19 | 遺伝的状態の処置のための方法および組成物 |
JP2022090175A Pending JP2022107776A (ja) | 2013-05-15 | 2022-06-02 | 遺伝的状態の処置のための方法および組成物 |
Country Status (8)
Country | Link |
---|---|
US (4) | US9873894B2 (ja) |
EP (2) | EP2997146A4 (ja) |
JP (4) | JP2016521975A (ja) |
CN (2) | CN116083487A (ja) |
AU (1) | AU2014265331B2 (ja) |
CA (1) | CA2910489A1 (ja) |
HK (1) | HK1223401A1 (ja) |
WO (1) | WO2014186585A2 (ja) |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016521555A (ja) * | 2013-06-05 | 2016-07-25 | デューク ユニバーシティ | Rnaガイド遺伝子編集及び遺伝子調節 |
WO2019098759A3 (ko) * | 2017-11-16 | 2019-07-18 | 재단법인 목암생명과학연구소 | 형질전환된 인간세포 및 이의 용도 |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
US10676735B2 (en) | 2015-07-22 | 2020-06-09 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
US10711256B2 (en) | 2012-04-27 | 2020-07-14 | Duke University | Genetic correction of mutated genes |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
JP2021500072A (ja) * | 2017-10-17 | 2021-01-07 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 血友病aに対する遺伝子編集用組成物及び方法 |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
JP2022512731A (ja) * | 2018-10-18 | 2022-02-07 | インテリア セラピューティクス,インコーポレーテッド | 第ix因子を発現するための組成物及び方法 |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US11427817B2 (en) | 2015-08-25 | 2022-08-30 | Duke University | Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US11970710B2 (en) | 2016-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
Families Citing this family (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256062A1 (en) | 2004-12-06 | 2010-10-07 | Howard Tommy E | Allelic Variants of Human Factor VIII |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
CA2877290A1 (en) | 2012-06-19 | 2013-12-27 | Daniel F. Voytas | Gene targeting in plants using dna viruses |
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
RS60838B1 (sr) | 2012-08-29 | 2020-10-30 | Sangamo Therapeutics Inc | Postupci i kompozicije za tretman genskog stanja |
DK2906684T3 (da) | 2012-10-10 | 2020-09-28 | Sangamo Therapeutics Inc | T-celle-modificerende forbindelser og anvendelser deraf |
CN104955943B (zh) | 2012-11-27 | 2018-09-25 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
EP2929017A4 (en) | 2012-12-05 | 2016-09-28 | Sangamo Biosciences Inc | METHODS AND COMPOSITIONS FOR REGULATION OF METABOLIC DISORDERS |
BR112015013311A2 (pt) | 2012-12-07 | 2017-11-14 | Haplomics Inc | indução de tolerancia e reparação de mutação do fator 8 |
CA2898184A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
AU2014218621B2 (en) | 2013-02-25 | 2019-11-07 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
ES2901396T3 (es) | 2013-03-14 | 2022-03-22 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico |
JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いたゲノム編集の治療的使用 |
EP3679785A3 (en) | 2013-04-05 | 2020-09-16 | Dow AgroSciences LLC | Methods and compositions for integration of an exogenous sequence within the genome of plants |
RS58255B1 (sr) | 2013-04-16 | 2019-03-29 | Regeneron Pharma | Ciljana modifikacija genoma pacova |
AU2014279694B2 (en) * | 2013-06-14 | 2020-07-23 | Cellectis | Methods for non-transgenic genome editing in plants |
EP3011032B1 (en) * | 2013-06-17 | 2019-10-16 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
CA2920899C (en) | 2013-08-28 | 2023-02-28 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
DE102013111099B4 (de) | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
WO2015057976A1 (en) | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
DK3441468T3 (da) | 2013-10-17 | 2021-07-26 | Sangamo Therapeutics Inc | Afgivelsesfremgangsmåder og sammensætninger til nukleasemedieret genom-manipulation |
KR102523466B1 (ko) | 2013-11-07 | 2023-04-20 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
ES2895069T3 (es) | 2013-11-13 | 2022-02-17 | Childrens Medical Center | Regulación de la expresión génica mediada por nucleasa |
CA2931848A1 (en) | 2013-12-09 | 2015-06-18 | Sangamo Biosciences, Inc. | Methods and compositions for genome engineering |
WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
RS60514B1 (sr) | 2014-02-03 | 2020-08-31 | Sangamo Therapeutics Inc | Postupci i sastavi za tretman beta talasemije |
WO2015127439A1 (en) | 2014-02-24 | 2015-08-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration |
WO2015134812A1 (en) | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
ES2879373T3 (es) | 2014-03-18 | 2021-11-22 | Sangamo Therapeutics Inc | Métodos y composiciones para la regulación de la expresión de proteínas de dedo de zinc |
WO2015148860A1 (en) * | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating beta-thalassemia |
EP3122880B1 (en) * | 2014-03-26 | 2021-05-05 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
WO2015164748A1 (en) | 2014-04-24 | 2015-10-29 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (tale) proteins |
KR102390629B1 (ko) | 2014-04-25 | 2022-04-26 | 칠드런'즈 메디컬 센터 코포레이션 | 헤모글로빈병증을 치료하기 위한 조성물 및 방법 |
AU2015255877B2 (en) | 2014-05-08 | 2020-03-26 | Chdi Foundation, Inc. | Methods and compositions for treating huntington's disease |
EP3142707A4 (en) | 2014-05-13 | 2018-02-21 | Sangamo Therapeutics, Inc. | Methods and compositions for prevention or treatment of a disease |
AU2015266767A1 (en) | 2014-05-30 | 2016-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods to treat latent viral infections |
WO2015188056A1 (en) | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
RU2704283C9 (ru) | 2014-06-06 | 2020-02-07 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для модификации целевого локуса |
CN106852157B (zh) | 2014-06-16 | 2022-04-12 | 约翰斯·霍普金斯大学 | 用于使用h1启动子表达crispr向导rna的组合物和方法 |
US20150376587A1 (en) * | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US9816074B2 (en) | 2014-07-25 | 2017-11-14 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
WO2016019144A2 (en) | 2014-07-30 | 2016-02-04 | Sangamo Biosciences, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
WO2016033246A1 (en) | 2014-08-27 | 2016-03-03 | Caribou Biosciences, Inc. | Methods for increasing cas9-mediated engineering efficiency |
EP3194570B1 (en) | 2014-09-16 | 2021-06-30 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
MX2017003815A (es) | 2014-09-24 | 2017-09-28 | Variantes de vector de virus asociado a adeno para edicion genomica de alta eficacia y sus metodos. | |
KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
US20170266320A1 (en) * | 2014-12-01 | 2017-09-21 | President And Fellows Of Harvard College | RNA-Guided Systems for In Vivo Gene Editing |
WO2016089433A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
US9888673B2 (en) | 2014-12-10 | 2018-02-13 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
EP3262172A2 (en) * | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of hemoglobinopathies |
CN104726449A (zh) * | 2015-03-23 | 2015-06-24 | 国家纳米科学中心 | 一种用于预防和/或治疗HIV的CRISPR-Cas9系统及其制备方法和用途 |
CN107787367B (zh) | 2015-04-06 | 2021-10-26 | 里兰斯坦福初级大学理事会 | 用于crispr/cas介导的基因调控的化学修饰的引导rna |
US20160324987A1 (en) * | 2015-04-15 | 2016-11-10 | Cedars-Sinai Medical Center | Use of crispr/cas9 as in vivo gene therapy to generate targeted genomic disruptions in genes bearing dominant mutations for retinitis pigmentosa |
EP3286571B1 (en) | 2015-04-24 | 2021-08-18 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
EP3763814A1 (en) | 2015-05-08 | 2021-01-13 | The Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
AU2016261358B2 (en) | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
KR20170141217A (ko) | 2015-05-12 | 2017-12-22 | 상가모 테라퓨틱스, 인코포레이티드 | 유전자 발현의 뉴클레아제-매개된 조절 |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
CN116334142A (zh) * | 2015-06-09 | 2023-06-27 | 爱迪塔斯医药公司 | 用于改善移植的crispr/cas相关方法和组合物 |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
IL295616A (en) | 2015-07-31 | 2022-10-01 | Us Health | Adapted cells and treatment methods |
CN104962523B (zh) * | 2015-08-07 | 2018-05-25 | 苏州大学 | 一种测定非同源末端连接修复活性的方法 |
CA3002647A1 (en) * | 2015-09-21 | 2017-03-30 | Arcturus Therapeutics, Inc. | Allele selective gene editing and uses thereof |
MX2018003491A (es) | 2015-09-23 | 2018-09-06 | Sangamo Therapeutics Inc | Represores de htt y usos de estos. |
CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
WO2017062983A1 (en) * | 2015-10-09 | 2017-04-13 | The Children's Hospital Of Philadelphia | Compositions and methods for treating huntington's disease and related disorders |
EP3362571A4 (en) | 2015-10-13 | 2019-07-10 | Duke University | GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS |
IL258821B (en) | 2015-10-23 | 2022-07-01 | Harvard College | Nucleobase editors and their uses |
AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
ES2942309T3 (es) * | 2015-11-04 | 2023-05-31 | Vertex Pharma | Materiales y métodos para el tratamiento de hemoglobinopatías |
EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
AU2016359629B2 (en) | 2015-11-23 | 2023-03-09 | Ranjan BATRA | Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9 |
AU2016374253B2 (en) | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
CA3008413A1 (en) | 2015-12-18 | 2017-06-22 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
WO2017115268A1 (en) * | 2015-12-28 | 2017-07-06 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
EA201891619A1 (ru) | 2016-01-11 | 2019-02-28 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Химерные белки и способы регулирования экспрессии генов |
EA201891614A1 (ru) | 2016-01-11 | 2019-02-28 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Химерные белки и способы иммунотерапии |
BR112018014288A2 (pt) | 2016-01-15 | 2018-12-18 | Univ Minnesota | métodos e composições para o tratamento de doença neurológica |
CA3011049A1 (en) | 2016-02-02 | 2017-08-10 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
MX2018011114A (es) * | 2016-03-14 | 2019-02-20 | Editas Medicine Inc | Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías. |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
EP3433363A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
US11236313B2 (en) | 2016-04-13 | 2022-02-01 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
CA3022611A1 (en) * | 2016-05-06 | 2017-11-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
US11471462B2 (en) | 2016-06-27 | 2022-10-18 | The Broad Institute, Inc. | Compositions and methods for detecting and treating diabetes |
AU2017305404B2 (en) | 2016-08-02 | 2023-11-30 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
IL264565B1 (en) | 2016-08-03 | 2024-03-01 | Harvard College | Adenosine nuclear base editors and their uses |
CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US20190185850A1 (en) | 2016-08-20 | 2019-06-20 | Avellino Lab Usa, Inc. | Single guide rna/crispr/cas9 systems, and methods of use thereof |
WO2020225754A1 (en) | 2019-05-06 | 2020-11-12 | Mcmullen Tara | Crispr gene editing for autosomal dominant diseases |
CN106244555A (zh) * | 2016-08-23 | 2016-12-21 | 广州医科大学附属第三医院 | 一种提高基因打靶的效率的方法及β‑球蛋白基因位点的碱基原位修复方法 |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
RS62758B1 (sr) | 2016-08-24 | 2022-01-31 | Sangamo Therapeutics Inc | Regulacija genske ekspresije korišćenjem inženjeringom nukleaza |
IL264792B2 (en) | 2016-08-24 | 2023-10-01 | Sangamo Therapeutics Inc | Engineered target-specific zinc-finger nucleases |
WO2018049009A2 (en) | 2016-09-07 | 2018-03-15 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
AU2017326234B2 (en) * | 2016-09-13 | 2020-05-14 | Academia Sinica | Methods for enhancing lifespan and/or treating cellular proliferative disorders by transplantation |
US11072660B2 (en) | 2016-10-03 | 2021-07-27 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
JP2019530464A (ja) | 2016-10-14 | 2019-10-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基エディターのaav送達 |
GB2605883B (en) | 2016-10-18 | 2023-03-15 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
AU2017345430A1 (en) | 2016-10-20 | 2019-05-02 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of Fabry disease |
CA3041668A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US20180135080A1 (en) | 2016-11-15 | 2018-05-17 | Genomic Vision Sa | Method for the monitoring of modified nucleases induced-gene editing events by molecular combing |
CN110214184A (zh) | 2016-12-01 | 2019-09-06 | 桑格摩生物治疗股份有限公司 | τ蛋白调节剂以及用于其递送的方法和组合物 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
BR112019015355A2 (pt) * | 2017-01-26 | 2020-05-19 | Sangamo Therapeutics Inc | modificação genética de células b |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
US10687520B2 (en) | 2017-03-07 | 2020-06-23 | The Board Of Regents Of The University Of Texas System | Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
EP3596217A1 (en) * | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
EA201992232A1 (ru) | 2017-03-22 | 2020-05-14 | Новартис Аг | Композиции и способы для иммуноонкологии |
WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
EP3615672A1 (en) | 2017-04-28 | 2020-03-04 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
US11655275B2 (en) | 2017-05-03 | 2023-05-23 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
CN111108207A (zh) * | 2017-06-02 | 2020-05-05 | 国家健康与医学研究院 | 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法 |
US10428319B2 (en) | 2017-06-09 | 2019-10-01 | Editas Medicine, Inc. | Engineered Cas9 nucleases |
CA3067316A1 (en) | 2017-06-15 | 2018-12-20 | Toolgen Incorporated | Platform for expressing protein of interest in liver |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
US20200140896A1 (en) * | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス,インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
CN107267516B (zh) * | 2017-07-28 | 2020-09-29 | 佛山科学技术学院 | 双sgRNA介导的基因精确修饰方法及应用 |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
EP3692063A1 (en) | 2017-10-03 | 2020-08-12 | Juno Therapeutics, Inc. | Hpv-specific binding molecules |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
WO2019094725A2 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
AU2018372763A1 (en) | 2017-11-21 | 2020-05-28 | Bayer Healthcare Llc | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa |
EP3714057A4 (en) * | 2017-11-21 | 2021-09-22 | Cargill, Incorporated | MODIFIED NUCLEASES IN THE PLANT GENERATION |
US20200370040A1 (en) * | 2017-12-07 | 2020-11-26 | Ramot At Tel-Aviv University Ltd. | Treatment for parkinsonian patients with mutations in the lrrk2 gene |
US11738047B2 (en) * | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
US10785574B2 (en) | 2017-12-14 | 2020-09-22 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
US11268077B2 (en) | 2018-02-05 | 2022-03-08 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
US11401512B2 (en) | 2018-02-08 | 2022-08-02 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
WO2019154313A1 (zh) | 2018-02-11 | 2019-08-15 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
CN108504685A (zh) * | 2018-03-27 | 2018-09-07 | 宜明细胞生物科技有限公司 | 一种利用CRISPR/Cas9系统同源重组修复IL-2RG缺陷基因的方法 |
SG11202009284TA (en) | 2018-04-05 | 2020-10-29 | Juno Therapeutics Inc | T cell receptors and engineered cells expressing same |
BR112020020073A2 (pt) | 2018-04-05 | 2021-01-05 | Juno Therapeutics Inc | Células t que expressam um receptor recombinante, polinucleotídeos relacionados e métodos |
CN112585276A (zh) | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
JP2021520781A (ja) | 2018-04-06 | 2021-08-26 | チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation | 体細胞リプログラミングおよびインプリンティングのモジュレートのための組成物および方法 |
CN112313246A (zh) | 2018-04-18 | 2021-02-02 | 桑格摩生物治疗股份有限公司 | 用于调节亨廷顿蛋白(htt)的锌指蛋白组合物 |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AU2019326408A1 (en) | 2018-08-23 | 2021-03-11 | Sangamo Therapeutics, Inc. | Engineered target specific base editors |
EP4234570A3 (en) | 2018-09-18 | 2023-12-13 | Sangamo Therapeutics, Inc. | Programmed cell death 1 (pd1) specific nucleases |
AU2019362000A1 (en) * | 2018-10-17 | 2021-05-20 | Bayer Healthcare Llc | Compositions and methods for delivering transgenes |
JP2022505381A (ja) * | 2018-10-18 | 2022-01-14 | インテリア セラピューティクス,インコーポレーテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法 |
MX2021004278A (es) * | 2018-10-18 | 2021-09-08 | Intellia Therapeutics Inc | Composiciones y metodos para la expresion de transgenes a partir de un locus de albumina. |
JP2022514954A (ja) * | 2018-12-23 | 2022-02-16 | シーエスエル・ベーリング・エルエルシー | キルスイッチを有するドナーt細胞 |
WO2020139807A2 (en) * | 2018-12-23 | 2020-07-02 | Csl Behring L.L.C. | Nanocapsules for the delivery of cell modulating agents |
EP3673920A1 (en) | 2018-12-28 | 2020-07-01 | Universität Wien | Polyphenol-peptide conjugates for nuclear-targeted delivery |
WO2020146805A1 (en) | 2019-01-11 | 2020-07-16 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
EP3826664A4 (en) | 2019-02-06 | 2022-10-26 | Sangamo Therapeutics, Inc. | METHOD FOR THE TREATMENT OF TYPE I MUCOPOLYSACCHARIDOSES |
WO2020191239A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
EP3946384A1 (en) | 2019-04-02 | 2022-02-09 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
US20220275402A1 (en) * | 2019-04-05 | 2022-09-01 | The Children's Hospital Of Philadelphia | Compositions and methods for in utero gene editing for monogenic lung disease |
SG11202111443SA (en) | 2019-04-23 | 2021-11-29 | Sangamo Therapeutics Inc | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
AU2020265741A1 (en) | 2019-05-01 | 2021-11-25 | Editas Medicine, Inc. | Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods |
CA3136742A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
MX2021015122A (es) | 2019-06-07 | 2022-04-06 | Regeneron Pharma | Animales no humanos que comprenden un locus de albumina humanizado. |
WO2021067233A1 (en) * | 2019-09-30 | 2021-04-08 | The Children's Medical Center Corporation | Bcl11a guide and base editor delivery |
KR20220104766A (ko) | 2019-11-22 | 2022-07-26 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 약물 전달을 위한 이온성 액체 |
WO2021113376A1 (en) * | 2019-12-02 | 2021-06-10 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epitope scanning |
WO2021216622A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom |
WO2021216623A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom |
EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법 |
US20230285549A1 (en) * | 2020-06-30 | 2023-09-14 | The Wistar Institute Of Anatomy & Biology | Cd4+helper epitopes and uses to enhance antigen-specific immune responses |
KR20220005208A (ko) * | 2020-07-06 | 2022-01-13 | 주식회사 지씨셀 | 면역원성이 감소된 신규한 이식용 세포 |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
EP4301755A1 (en) | 2021-03-03 | 2024-01-10 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
TW202305118A (zh) | 2021-03-23 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途 |
WO2023004411A1 (en) * | 2021-07-23 | 2023-01-26 | Icahn School Of Medicine At Mount Sinai | A method for in vivo gene therapy to cure scd without myeloablative toxicity |
CA3230927A1 (en) | 2021-09-10 | 2023-03-16 | Agilent Technologies, Inc. | Guide rnas with chemical modification for prime editing |
CA3233824A1 (en) | 2021-10-08 | 2023-04-13 | Samir Mitragotri | Ionic liquids for drug delivery |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
WO2024023802A2 (en) * | 2022-07-29 | 2024-02-01 | Crispr Therapeutics Ag | Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010539930A (ja) * | 2007-09-27 | 2010-12-24 | ダウ・アグロサイエンス・エル・エル・シー | 5−エノールピルビルシキミ酸−3−リン酸シンターゼ遺伝子をターゲッティングする改変ジンクフィンガータンパク質 |
JP2012511926A (ja) * | 2008-12-17 | 2012-05-31 | ダウ・アグロサイエンス・エル・エル・シー | Zp15遺伝子座内への標的組込み |
WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
WO2014089290A1 (en) * | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
WO2014093661A2 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
WO2014099744A1 (en) * | 2012-12-17 | 2014-06-26 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US5591616A (en) | 1992-07-07 | 1997-01-07 | Japan Tobacco, Inc. | Method for transforming monocotyledons |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE310812T1 (de) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
WO1995025809A1 (en) | 1994-03-23 | 1995-09-28 | Ohio University | Compacted nucleic acids and their delivery to cells |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
AU5588298A (en) | 1996-12-02 | 1998-06-29 | Cell Genesys, Inc. | Adeno-associated viral vector-mediated delivery of dna to cells of the liver |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
ATE309536T1 (de) | 1999-12-06 | 2005-11-15 | Sangamo Biosciences Inc | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen |
ATE483970T1 (de) | 2000-02-08 | 2010-10-15 | Sangamo Biosciences Inc | Zellen zur entdeckung von medikamenten |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2003016496A2 (en) | 2001-08-20 | 2003-02-27 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
CN100575485C (zh) | 2002-01-23 | 2009-12-30 | 犹他大学研究基金会 | 使用锌指核酸酶的定向染色体诱变 |
CA2479858A1 (en) | 2002-03-21 | 2003-10-02 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
ES2407857T5 (es) | 2004-04-30 | 2017-07-31 | Dow Agrosciences Llc | Nuevo gen de resistencia a los herbicidas |
US20080131962A1 (en) | 2006-05-25 | 2008-06-05 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2006033859A2 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
MX2007013757A (es) | 2005-05-05 | 2008-01-24 | Univ Arizona | Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas. |
CA2615532C (en) | 2005-07-26 | 2016-06-28 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
AU2007267874B2 (en) | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
JP5188504B2 (ja) | 2006-11-13 | 2013-04-24 | サンガモ バイオサイエンシズ インコーポレイテッド | ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物 |
ATE489465T1 (de) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
US20090123626A1 (en) | 2007-09-28 | 2009-05-14 | J.R. Simplot Company | Reduced acrylamide plants and foods |
JP5507459B2 (ja) | 2007-10-05 | 2014-05-28 | ダウ アグロサイエンシィズ エルエルシー | 植物細胞に分子性物質を移行させる方法 |
JP5908725B2 (ja) | 2008-08-22 | 2016-04-26 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的一本鎖開裂および標的組込みのための方法、並びに組成物 |
WO2010030963A2 (en) * | 2008-09-15 | 2010-03-18 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
CA2755192C (en) | 2009-03-20 | 2018-09-11 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
KR20120097483A (ko) * | 2009-07-24 | 2012-09-04 | 시그마-알드리치 컴퍼니., 엘엘씨 | 게놈 편집을 위한 방법 |
EP2727600B1 (en) | 2009-07-28 | 2019-03-27 | Sangamo Therapeutics, Inc. | Zinc finger fusion proteins for repressing a huntington gene |
BR122019025207B1 (pt) | 2009-10-22 | 2022-10-04 | Sangamo Biosciences, Inc. | Proteína de dedo de zinco de ocorrência não natural e proteína de fusão |
CA2787494C (en) | 2010-01-22 | 2019-09-17 | Dow Agrosciences Llc | Targeted genomic alteration |
PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US8771985B2 (en) | 2010-04-26 | 2014-07-08 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using zinc-finger nucleases |
WO2011146121A1 (en) | 2010-05-17 | 2011-11-24 | Sangamo Biosciences, Inc. | Novel dna-binding proteins and uses thereof |
AU2011312562B2 (en) | 2010-09-27 | 2014-10-09 | Sangamo Therapeutics, Inc. | Methods and compositions for inhibiting viral entry into cells |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
US8969254B2 (en) | 2010-12-16 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Oligonucleotide array for tissue typing |
US20120214241A1 (en) | 2010-12-22 | 2012-08-23 | Josee Laganiere | Zinc finger nuclease modification of leucine rich repeat kinase 2 (lrrk2) mutant fibroblasts and ipscs |
CN106791842A (zh) | 2011-09-06 | 2017-05-31 | 英特尔公司 | 分析辅助编码 |
US9394545B2 (en) * | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
BR112014020625A2 (pt) * | 2012-02-24 | 2017-07-04 | Hutchinson Fred Cancer Res | polinucleotídeo, polipeptídeo, composição, célula e célula tronco editada por genoma |
AR092255A1 (es) | 2012-08-29 | 2015-04-08 | Halliburton Energy Services Inc | Composiciones de selladores a base de resina que comprenden polvo de horno de cemento y sus metodos de uso |
RS60838B1 (sr) | 2012-08-29 | 2020-10-30 | Sangamo Therapeutics Inc | Postupci i kompozicije za tretman genskog stanja |
IL239317B (en) * | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
JP2016522679A (ja) * | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いたゲノム編集の治療的使用 |
WO2014182700A1 (en) | 2013-05-10 | 2014-11-13 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
-
2014
- 2014-05-15 EP EP14797155.0A patent/EP2997146A4/en not_active Withdrawn
- 2014-05-15 AU AU2014265331A patent/AU2014265331B2/en active Active
- 2014-05-15 WO PCT/US2014/038216 patent/WO2014186585A2/en active Application Filing
- 2014-05-15 US US14/278,903 patent/US9873894B2/en active Active
- 2014-05-15 CN CN202211659829.3A patent/CN116083487A/zh active Pending
- 2014-05-15 CA CA2910489A patent/CA2910489A1/en active Pending
- 2014-05-15 EP EP20173697.2A patent/EP3730615A3/en active Pending
- 2014-05-15 CN CN201480039996.5A patent/CN105683376A/zh active Pending
- 2014-05-15 JP JP2016514094A patent/JP2016521975A/ja not_active Withdrawn
-
2015
- 2015-12-10 US US14/965,629 patent/US9902974B2/en active Active
-
2016
- 2016-10-12 HK HK16111740.2A patent/HK1223401A1/zh unknown
-
2017
- 2017-12-19 US US15/847,582 patent/US10196651B2/en active Active
-
2018
- 2018-01-16 US US15/872,644 patent/US10196652B2/en active Active
-
2019
- 2019-01-24 JP JP2019010055A patent/JP6964103B2/ja active Active
-
2020
- 2020-05-19 JP JP2020087329A patent/JP2020120690A/ja not_active Withdrawn
-
2022
- 2022-06-02 JP JP2022090175A patent/JP2022107776A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010539930A (ja) * | 2007-09-27 | 2010-12-24 | ダウ・アグロサイエンス・エル・エル・シー | 5−エノールピルビルシキミ酸−3−リン酸シンターゼ遺伝子をターゲッティングする改変ジンクフィンガータンパク質 |
JP2012511926A (ja) * | 2008-12-17 | 2012-05-31 | ダウ・アグロサイエンス・エル・エル・シー | Zp15遺伝子座内への標的組込み |
WO2013176772A1 (en) * | 2012-05-25 | 2013-11-28 | The Regents Of The University Of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
WO2014089290A1 (en) * | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
WO2014093661A2 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
WO2014099744A1 (en) * | 2012-12-17 | 2014-06-26 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
Non-Patent Citations (5)
Title |
---|
CELL (FEB-2013) VOL.152, ISSUE 5, P.1173-1183, SUPPLEMENTARY INFORMATION, JPN6018002512, ISSN: 0004011695 * |
NAT. BIOTECHNOL. (JAN-2013) VOL.31, NO.3, P.230-232, SUPPLEMENTARY INFORMATION, JPN6018002510, ISSN: 0004011694 * |
SCIENCE (JAN-2013) VOL.339, ISSUE 6121, P.819-823, SUPPLEMENTARY MATERIALS, JPN6018002504, ISSN: 0004011692 * |
SCIENCE (JAN-2013) VOL.339, ISSUE 6121, P.823-826, SUPPLEMENTARY MATERIALS, JPN6018002507, ISSN: 0004011693 * |
TRENDS BIOTECHNOL. (09-MAY-2013) VOL.31, NO.7, P.397-405, JPN6018002514, ISSN: 0004011696 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10711256B2 (en) | 2012-04-27 | 2020-07-14 | Duke University | Genetic correction of mutated genes |
US11041173B2 (en) | 2012-12-12 | 2021-06-22 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US10930367B2 (en) | 2012-12-12 | 2021-02-23 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for Cas enzymes or CRISPR-Cas systems for target sequences and conveying results thereof |
US10745714B2 (en) | 2013-06-05 | 2020-08-18 | Duke University | RNA-guided gene editing and gene regulation |
JP2016521555A (ja) * | 2013-06-05 | 2016-07-25 | デューク ユニバーシティ | Rnaガイド遺伝子編集及び遺伝子調節 |
US10704060B2 (en) | 2013-06-05 | 2020-07-07 | Duke University | RNA-guided gene editing and gene regulation |
US11008588B2 (en) | 2013-06-17 | 2021-05-18 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
US10946108B2 (en) | 2013-06-17 | 2021-03-16 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for targeting disorders and diseases using viral components |
US10577630B2 (en) | 2013-06-17 | 2020-03-03 | The Broad Institute, Inc. | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
US11597949B2 (en) | 2013-06-17 | 2023-03-07 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10711285B2 (en) | 2013-06-17 | 2020-07-14 | The Broad Institute, Inc. | Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation |
US10781444B2 (en) | 2013-06-17 | 2020-09-22 | The Broad Institute, Inc. | Functional genomics using CRISPR-Cas systems, compositions, methods, screens and applications thereof |
US10851357B2 (en) | 2013-12-12 | 2020-12-01 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US11155795B2 (en) | 2013-12-12 | 2021-10-26 | The Broad Institute, Inc. | CRISPR-Cas systems, crystal structure and uses thereof |
US11591581B2 (en) | 2013-12-12 | 2023-02-28 | The Broad Institute, Inc. | Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders |
US11407985B2 (en) | 2013-12-12 | 2022-08-09 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for genome editing |
US11597919B2 (en) | 2013-12-12 | 2023-03-07 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US10550372B2 (en) | 2013-12-12 | 2020-02-04 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems |
US11624078B2 (en) | 2014-12-12 | 2023-04-11 | The Broad Institute, Inc. | Protected guide RNAS (pgRNAS) |
US10696986B2 (en) | 2014-12-12 | 2020-06-30 | The Board Institute, Inc. | Protected guide RNAS (PGRNAS) |
US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
US11155796B2 (en) | 2015-02-09 | 2021-10-26 | Duke University | Compositions and methods for epigenome editing |
US10494621B2 (en) | 2015-06-18 | 2019-12-03 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US10876100B2 (en) | 2015-06-18 | 2020-12-29 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
US11578312B2 (en) | 2015-06-18 | 2023-02-14 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation |
US10676735B2 (en) | 2015-07-22 | 2020-06-09 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
US11427817B2 (en) | 2015-08-25 | 2022-08-30 | Duke University | Compositions and methods of improving specificity in genomic engineering using RNA-guided endonucleases |
US11970710B2 (en) | 2016-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
JP2021500072A (ja) * | 2017-10-17 | 2021-01-07 | クリスパー セラピューティクス アクチェンゲゼルシャフト | 血友病aに対する遺伝子編集用組成物及び方法 |
JP2021503284A (ja) * | 2017-11-16 | 2021-02-12 | モガム・インスティテュート・フォー・バイオメディカル・リサーチMogam Institute For Biomedical Research | 形質転換ヒト細胞およびその使用 |
WO2019098759A3 (ko) * | 2017-11-16 | 2019-07-18 | 재단법인 목암생명과학연구소 | 형질전환된 인간세포 및 이의 용도 |
JP2022512731A (ja) * | 2018-10-18 | 2022-02-07 | インテリア セラピューティクス,インコーポレーテッド | 第ix因子を発現するための組成物及び方法 |
WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
Also Published As
Publication number | Publication date |
---|---|
JP2022107776A (ja) | 2022-07-22 |
WO2014186585A3 (en) | 2015-01-15 |
US9902974B2 (en) | 2018-02-27 |
AU2014265331B2 (en) | 2019-12-05 |
CN105683376A (zh) | 2016-06-15 |
EP2997146A4 (en) | 2017-04-26 |
US20180148740A1 (en) | 2018-05-31 |
EP3730615A3 (en) | 2020-12-09 |
US9873894B2 (en) | 2018-01-23 |
HK1223401A1 (zh) | 2017-07-28 |
US10196652B2 (en) | 2019-02-05 |
WO2014186585A2 (en) | 2014-11-20 |
EP2997146A2 (en) | 2016-03-23 |
CA2910489A1 (en) | 2014-11-20 |
JP2020120690A (ja) | 2020-08-13 |
US10196651B2 (en) | 2019-02-05 |
AU2014265331A1 (en) | 2015-11-12 |
US20150056705A1 (en) | 2015-02-26 |
US20160090607A1 (en) | 2016-03-31 |
EP3730615A2 (en) | 2020-10-28 |
US20180119175A1 (en) | 2018-05-03 |
CN116083487A (zh) | 2023-05-09 |
JP2019058193A (ja) | 2019-04-18 |
JP6964103B2 (ja) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6964103B2 (ja) | 遺伝的状態の処置のための方法および組成物 | |
US9970001B2 (en) | Methods and compositions for nuclease design | |
JP6629917B2 (ja) | 遺伝子疾患の治療のための方法および組成物 | |
JP2024009129A (ja) | サイトカイン誘導性sh2含有タンパク質(cish)遺伝子の遺伝子改変 | |
BR112015003815B1 (pt) | Proteína de dedo de zinco, proteína de fusão, usos das mesmas, e kit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190124 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190124 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190204 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190205 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190405 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20190409 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20190917 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200219 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200519 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20200715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201008 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210205 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210304 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210304 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20210421 |